bupropion has been researched along with Chronic Insomnia in 20 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
| Excerpt | Relevance | Reference |
|---|---|---|
| "These preliminary results support the feasibility and safety of conducting adequately powered, placebo-controlled efficacy studies of varenicline and bupropion XL for adolescent smoking cessation." | 9.16 | Varenicline versus bupropion XL for smoking cessation in older adolescents: a randomized, double-blind pilot trial. ( Carpenter, MJ; Gray, KM; Klintworth, EM; Lewis, AL; Upadhyaya, HP, 2012) |
| "Sustained-release bupropion (bupropion SR) was first launched in the US in 1997 as an aid to smoking cessation and has since been launched in many other countries." | 8.81 | Tolerability and safety of sustained-release bupropion in the management of smoking cessation. ( Aubin, HJ, 2002) |
| "These preliminary results support the feasibility and safety of conducting adequately powered, placebo-controlled efficacy studies of varenicline and bupropion XL for adolescent smoking cessation." | 5.16 | Varenicline versus bupropion XL for smoking cessation in older adolescents: a randomized, double-blind pilot trial. ( Carpenter, MJ; Gray, KM; Klintworth, EM; Lewis, AL; Upadhyaya, HP, 2012) |
| "Outpatients with moderate to severe major depressive disorder (DSM-IV) received bupropion SR (100-300 mg/day) or sertraline (50-200 mg/day) for 16 weeks." | 5.08 | Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. ( Ascher, JA; Hughes, AR; Johnston, JA; Kavoussi, RJ; Segraves, RT, 1997) |
| "Sustained-release bupropion (bupropion SR) was first launched in the US in 1997 as an aid to smoking cessation and has since been launched in many other countries." | 4.81 | Tolerability and safety of sustained-release bupropion in the management of smoking cessation. ( Aubin, HJ, 2002) |
| " Importantly, the appetite suppressant-induced weight loss and locomotion were markedly reduced by intragastric (and intra-NAc shell) infusions of dopamine antagonists SCH-23390 (D1 receptor) or raclopride (D2 receptor)." | 3.81 | D1 and D2 antagonists reverse the effects of appetite suppressants on weight loss, food intake, locomotion, and rebalance spiking inhibition in the rat NAc shell. ( Elias, D; Gutierrez, R; Kalyanasundar, B; Luna, A; Moreno, MG; Perez, CI; Simon, SA; Solorio, J, 2015) |
| "Most patients with major depressive disorder (MDD) report clinically significant sleep problems." | 2.80 | Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report. ( Luther, JF; Rush, AJ; Sung, SC; Trivedi, MH; Wisniewski, SR, 2015) |
| "Flexibly dosed triple-combination pharmacotherapy for up to 6 months was more effective than standard-duration nicotine patch therapy for outpatient smokers with medical illnesses." | 2.74 | Triple-combination pharmacotherapy for medically ill smokers: a randomized trial. ( Bover, MT; Carson, JL; Foulds, J; Greenhaus, S; Hoover, DR; Schmelzer, AC; Steinberg, MB, 2009) |
| "Bupropion XL was superior to placebo at endpoint in reducing the IDS-IVR-30 total score (p = ." | 2.72 | Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study. ( Hampton, KD; Jefferson, JW; Krishen, A; Modell, JG; Nelson, JC; Rush, AJ; VanMeter, SA; Wightman, DS, 2006) |
| "Trazodone is an effective hypnotic for patients with antidepressant-associated insomnia." | 2.67 | Trazodone for antidepressant-associated insomnia. ( Adler, LA; Nierenberg, AA; Peselow, E; Rosenthal, M; Zornberg, G, 1994) |
| "Bupropion was studied in four double-blind, placebo-controlled trials (N = 360) at dosages of 300-750 mg/day." | 2.65 | Methodologic approach to adverse events applied to bupropion clinical trials. ( Cato, AE; Cook, L; Heatherington, D; Starbuck, R, 1983) |
| "For a population with a yearly recurrence rate of 30%, the NNTB is 8 (95% CI 6 to 12)." | 2.61 | Second-generation antidepressants for preventing seasonal affective disorder in adults. ( Forneris, CA; Gartlehner, G; Gaynes, BN; Greenblatt, A; Lux, LJ; Morgan, LC; Nussbaumer-Streit, B; Van Noord, MG; Winkler, D; Wipplinger, J, 2019) |
| "Bupropion is a cytochrome p450 2D6 inhibitor and care must be taken when coprescribing with drugs cleared by this enzyme and when coprescribing with drugs that lower seizure threshold." | 2.43 | Bupropion. ( Wilkes, S, 2006) |
| "Insomnia and daytime sleepiness are often associated with depression." | 2.42 | Daytime sleepiness and insomnia as correlates of depression. ( Fava, M, 2004) |
| "Study data demonstrate that seizure incidence, which is a concern with high-dose IR, is substantially lower with the new SR formulation." | 2.40 | Bupropion sustained release: side effect profile. ( Settle, EC, 1998) |
| "Despite the superior side effect profile of the newer antidepressants over the tricyclics and monoamine oxidase inhibitors, all newer antidepressants are associated with a wide array of side effects." | 1.31 | The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists. ( Dording, CM; Fava, M; Gordon, J; Kornbluh, R; Mischoulon, D; Nierenberg, AA; Petersen, TJ; Rosenbaum, JE, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.00) | 18.7374 |
| 1990's | 3 (15.00) | 18.2507 |
| 2000's | 9 (45.00) | 29.6817 |
| 2010's | 5 (25.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Scala, M | 1 |
| Fanelli, G | 1 |
| De Ronchi, D | 1 |
| Serretti, A | 1 |
| Fabbri, C | 1 |
| Gandotra, K | 1 |
| Jaskiw, GE | 1 |
| Williams, SG | 1 |
| Fuller, MA | 1 |
| Chen, P | 1 |
| Wilson, B | 1 |
| ElGhoul, R | 1 |
| Konicki, E | 1 |
| Strohl, KP | 1 |
| Gartlehner, G | 1 |
| Nussbaumer-Streit, B | 1 |
| Gaynes, BN | 1 |
| Forneris, CA | 1 |
| Morgan, LC | 1 |
| Greenblatt, A | 1 |
| Wipplinger, J | 1 |
| Lux, LJ | 1 |
| Van Noord, MG | 1 |
| Winkler, D | 1 |
| Sung, SC | 1 |
| Wisniewski, SR | 1 |
| Luther, JF | 1 |
| Trivedi, MH | 1 |
| Rush, AJ | 2 |
| Kalyanasundar, B | 1 |
| Perez, CI | 1 |
| Luna, A | 1 |
| Solorio, J | 1 |
| Moreno, MG | 1 |
| Elias, D | 1 |
| Simon, SA | 1 |
| Gutierrez, R | 1 |
| Steinberg, MB | 1 |
| Greenhaus, S | 1 |
| Schmelzer, AC | 1 |
| Bover, MT | 1 |
| Foulds, J | 1 |
| Hoover, DR | 1 |
| Carson, JL | 1 |
| Gray, KM | 1 |
| Carpenter, MJ | 1 |
| Lewis, AL | 1 |
| Klintworth, EM | 1 |
| Upadhyaya, HP | 1 |
| Dickson, GM | 1 |
| Aubin, HJ | 1 |
| Paul, MA | 1 |
| Gray, G | 1 |
| Kenny, G | 1 |
| Lange, M | 1 |
| Dording, CM | 1 |
| Mischoulon, D | 1 |
| Petersen, TJ | 1 |
| Kornbluh, R | 1 |
| Gordon, J | 1 |
| Nierenberg, AA | 2 |
| Rosenbaum, JE | 1 |
| Fava, M | 2 |
| Csoka, AB | 1 |
| Shipko, S | 1 |
| Jefferson, JW | 1 |
| Nelson, JC | 1 |
| VanMeter, SA | 1 |
| Krishen, A | 1 |
| Hampton, KD | 1 |
| Wightman, DS | 1 |
| Modell, JG | 1 |
| Wilkes, S | 1 |
| Boutou, AK | 1 |
| Tsiata, EA | 1 |
| Pataka, A | 1 |
| Kontou, PK | 1 |
| Pitsiou, GG | 1 |
| Argyropoulou, P | 1 |
| Cato, AE | 1 |
| Cook, L | 1 |
| Starbuck, R | 1 |
| Heatherington, D | 1 |
| Adler, LA | 1 |
| Peselow, E | 1 |
| Zornberg, G | 1 |
| Rosenthal, M | 1 |
| Kavoussi, RJ | 1 |
| Segraves, RT | 1 |
| Hughes, AR | 1 |
| Ascher, JA | 1 |
| Johnston, JA | 1 |
| Settle, EC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Flexibly-Dosed Combination Pharmacotherapy Versus Standard-Dosed Nicotine Patch Alone for Smokers With Medical Illness[NCT00770666] | Phase 4 | 127 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| Music to Improve Sleep Quality in Adults With Depression and Insomnia: a Randomized Controlled Trial Using Mixed Methods[NCT03676491] | 112 participants (Actual) | Interventional | 2018-05-23 | Completed | |||
| An 8 Week, Multicenter, Randomized, Double-blind, Placebo Controlled Comparison of the Efficacy of Extended Release Bupropion Hydrochloride and Placebo in the Treatment of Adult Outpatients With Major Depressive Disorder With Lethargic Symptoms[NCT00064467] | Phase 3 | 268 participants | Interventional | 2003-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for bupropion and Chronic Insomnia
| Article | Year |
|---|---|
Clinical specificity profile for novel rapid acting antidepressant drugs.
Topics: Antidepressive Agents; Bupropion; Comorbidity; Depressive Disorder, Major; Humans; Sleep Initiation | 2023 |
Second-generation antidepressants for preventing seasonal affective disorder in adults.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Diarrhea; Headache; Humans; Incidence; N | 2019 |
Tolerability and safety of sustained-release bupropion in the management of smoking cessation.
Topics: Bupropion; Clinical Trials as Topic; Consumer Product Safety; Delayed-Action Preparations; Dopamine | 2002 |
Daytime sleepiness and insomnia as correlates of depression.
Topics: Antidepressive Agents; Benzhydryl Compounds; Bupropion; Comorbidity; Depressive Disorder; Disorders | 2004 |
Bupropion.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Dizziness; Headache; Humans; Models, Biological | 2006 |
Bupropion sustained release: side effect profile.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Delayed-Actio | 1998 |
8 trials available for bupropion and Chronic Insomnia
| Article | Year |
|---|---|
Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; Bupropion; Citalopram; Comorbidit | 2015 |
Triple-combination pharmacotherapy for medically ill smokers: a randomized trial.
Topics: Administration, Cutaneous; Administration, Inhalation; Adolescent; Adult; Aged; Anxiety; Bupropion; | 2009 |
Varenicline versus bupropion XL for smoking cessation in older adolescents: a randomized, double-blind pilot trial.
Topics: Adolescent; Benzazepines; Bupropion; Double-Blind Method; Female; Humans; Male; Nausea; Pilot Projec | 2012 |
The impact of bupropion on psychomotor performance.
Topics: Adult; Aerospace Medicine; Antidepressive Agents, Second-Generation; Bupropion; Cross-Over Studies; | 2002 |
Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.
Topics: 4-Aminopyridine; Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Depressi | 2006 |
Methodologic approach to adverse events applied to bupropion clinical trials.
Topics: Akathisia, Drug-Induced; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Depressive Diso | 1983 |
Trazodone for antidepressant-associated insomnia.
Topics: Adult; Bupropion; Confidence Intervals; Depressive Disorder; Dose-Response Relationship, Drug; Doubl | 1994 |
Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients.
Topics: 1-Naphthylamine; Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents; Bupropion; Delayed | 1997 |
6 other studies available for bupropion and Chronic Insomnia
| Article | Year |
|---|---|
Development of Insomnia Associated With Different Formulations of Bupropion.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depressive Disorde | 2021 |
D1 and D2 antagonists reverse the effects of appetite suppressants on weight loss, food intake, locomotion, and rebalance spiking inhibition in the rat NAc shell.
Topics: Action Potentials; Animals; Appetite Depressants; Benzazepines; Bupropion; Diethylpropion; Dopamine | 2015 |
Menopause management: how you can do better.
Topics: Acupuncture Therapy; Adjuvants, Immunologic; Administration, Cutaneous; Administration, Topical; Aff | 2012 |
The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists.
Topics: Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Bupropion; Critical Pathways; Dat | 2002 |
Persistent sexual side effects after SSRI discontinuation.
Topics: Adult; Androgens; Anxiety; Bupropion; Cabergoline; Citalopram; Depressive Disorder; Dopamine Agonist | 2006 |
Smoking cessation in clinical practice: predictors of six-month continuous abstinence in a sample of Greek smokers.
Topics: Adult; Bupropion; Case-Control Studies; Female; Follow-Up Studies; Greece; Humans; Male; Middle Aged | 2008 |